



February 13, 2026

To,

General Manager, Listing Department, Bombay Stock Exchange Limited, P.J. Towers, Dalal Street, Mumbai – 400 001 Company code: 533333	The Manager, Listing & Compliance Department The National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai - 400051 Company code: FCL
---	---

Subject: Outcome of Board Meeting

Dear Sir/Madam,

Pursuant to Regulation 30, 33 and Schedule III (Part A) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the meeting of the Board of Directors held on Friday, February 13, 2026, which commenced at **04.40 P.M.** and concluded at **05.50 P.M.** has inter-alia considered and approved;

1. The Unaudited Standalone and Consolidated Financial Results of the Company and the Limited Review Reports of the Statutory Auditors thereon for the quarter ended December 31, 2025.

We enclosed a copy of the Standalone and Consolidated Unaudited Financial Results along with the Limited Review Report of the Statutory Auditors thereon for the quarter and nine months ended December 31, 2025.

Highlights of Consolidated Business

a) Consolidated Quarter Q3-FY 2025-2026 (Q-o-Q Basis)

1. Total Income from Operation for the Quarter has **increased to Rs. 19,046 Lakhs** from **Rs. 14,543 Lakhs** i.e., a **growth of 30.96 %**.
2. Profit after tax (PAT) for the quarter ended has **increased to Rs. 3,012 Lakhs** from **Rs. 2,608 Lakhs** i.e., a **growth of 15.50 %**.
3. Operational EBITDA for the quarter has **increased to Rs. 3,484 Lakhs** from **Rs. 3,103 Lakhs** i.e., a **growth of 12.28 %**, demonstrating strong operational efficiency.

b) Consolidated Quarter Q3-FY 2025-2026 (Y-o-Y Basis)

1. Total Income from Operation for the Quarter has **increased to Rs. 19,046 Lakhs** from **Rs. 13,091 Lakhs** i.e., a **growth of 45.49 %**.
2. Profit after tax (PAT) for the quarter ended has **increased to Rs. 3,012 Lakhs** from **Rs. 2,783 Lakhs** i.e., a **growth of 8.23 %**.

Other Highlights of Q3 for the Financial Year 2025-2026

1. The consolidated Return on Invested Capital (ROIC) for Q3 FYE 2026 is **26.82 %**.
2. During the quarter, Fineotex has successfully completed the acquisition of U.S.-based specialty chemical manufacturing group CrudeChem Technologies (CCT Group) through its subsidiary. This strategic acquisition marks a transformative milestone in the Company's journey toward global expansion and strengthens its technological capabilities and leadership in high-performance and sustainable chemical solutions.
The CrudeChem Technologies Group, is a well-established U.S. based specialty chemical manufacturer of advanced chemical fluid additives and comprehensive oilfield chemicals solutions for the global oil and gas sector.
3. During the quarter, the Company received the subscription amount of Rs.35.68 crores approximately pursuant to the conversion of 75% of the outstanding warrants. Out of the said conversion, the Promoter has exercised 5,00,000 warrants at an aggregate consideration of Rs. 17.30s crores approximately at issue price Rs. 346 per share (i.e Rs. 34.60 per share post bonus and sub-division)
4. **Volume Growth:** The volume of the consolidated business for the Quarter ended has increased by approximately **39 %** on Y-o-Y basis.

Kindly take the above information on your records and oblige.

Thanking you,

Yours faithfully,

For FINEOTEX CHEMICAL LIMITED

Sanjay Tibrewala

Executive Director and CFO

DIN: 00218525




Encl: As above

Independent Auditor's Review Report on the Consolidated Unaudited Quarter and Nine months ended December 31,2025 Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

**Review Report to
The Board of Directors
Fineotex Chemical Limited**

1. We have reviewed the accompanying Statement of Consolidated Unaudited financial results of Fineotex Chemical Limited (the "Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter and nine months ended December 31, 2025 (the "Statement") attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under Section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the SEBI Circular CIR/CFD/CMD1/44/2019 dated 29 March 2019 issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), to the extent applicable.



Fineotex Chemical Limited**Independent Auditor's Review Report on the Consolidated Unaudited Quarter and Nine months ended December 31, 2025 Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.****4. The Statement includes the results of the following entities:**

Name of Entity	Relationship
1. Manya Manufacturing India Private Limited (Formerly Known as Manya Steels Private Limited)	Wholly Owned Subsidiary
2. Fineotex Biotex Healthguard FZE (Formerly Known as Fineotex Specialities FZE)	Wholly Owned Subsidiary
3. Fineotex Malaysia Limited	
4. FSPL Specialities Private Limited (Formerly Known as Fineotex Specialities Private Limited)	Wholly Owned Subsidiary Wholly Owned Subsidiary
5. Finoclean Specialities Private Limited	Wholly Owned Subsidiary
Subsidiaries of Fineotex Malaysia Limited	
6. BT Chemicals SDN.BHD.	Subsidiary
7. BT Biotex SDN.BHD.	Subsidiary
8. Rovatex SDN. BHD.	Subsidiary
9. BT. Biotex Limited	Wholly Owned Subsidiary
Subsidiaries of Fineotex Biotex Healthguard FZE	
10. FrackMex Equipment and Services LLC	Subsidiary
11. CrudeChem Technology LLC	Subsidiary
12. Oil Pro Advantage INC.	Subsidiary
13. Lonestar Technoboost LLC	Subsidiary

- 5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the unreviewed and unaudited interim financial information prepared and furnished to us by the management and approved by the Board of Directors of the Parent Company referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS 34 specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.**



Fineotex Chemical Limited
Independent Auditor's Review Report on the Consolidated Unaudited Quarter and Nine months ended December 31, 2025 Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

6. The consolidated unaudited financial results includes the interim financial information of (13) thirteen subsidiaries which have not been reviewed and are not audited, whose interim financial information reflects (before eliminating intercompany transactions) total revenues of ₹ 8,271.17 Lakhs and ₹ 18,315.99 Lakhs for the quarter and nine months ended December 31, 2025 respectively, total net profit/ (loss) after tax of ₹ 446.32 Lakhs and ₹ 1,046.57 Lakhs, for the quarter and nine months ended December 31, 2025 respectively. These interim financial information are not reviewed and are unaudited and have been prepared and furnished to us by the management of the Parent Company and in our opinion on the unaudited consolidated financial results, in so far as it relates to the amounts included in the consolidated unaudited financial results in respect of these subsidiary companies, is based solely on such unreviewed and unaudited interim financial information prepared and furnished to us by the management of the Parent Company and approved by the Board of Directors of the Parent Company.

Our Conclusion on the Statement is not modified in respect of our reliance on the unreviewed and unaudited interim financial information of these subsidiary companies certified by the Management of the Parent Company and approved by the Board of Directors of the Parent Company.

For ASL & Co.
Chartered Accountants
(Regn No. 101921W)



(Shikha Jain)

Partner

Membership No.: 136484

UDIN: 26136484CIGRFW6921

Place: Mumbai

Date: February 13, 2026



FCL FINEOTEX CHEMICAL LIMITED

(Company Identification Number: L24100MH2004PLC144295)

Regd. Off.: 42/43, Manorama Chambers, S V Road, Bandra (W), Mumbai 400050

Tel: 022-26559174-77, Fax: 022-22659178, Email: info@fineotex.com, Web: www.fineotex.com

(₹ In lakhs)

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2025						
PARTICULARS	Quarter ended			Nine months ended		Year Ended
	31-Dec-25	30-Sep-25	31-Dec-24	31-Dec-25	31-Dec-24	31-Mar-25
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Income						
a) Revenue from operation	18,371.39	13,770.54	12,591.95	45,849.14	41,354.74	53,333.28
b) Other Income	674.86	771.97	498.60	2,361.31	1,676.08	2,430.67
Total Income	19,046.25	14,542.51	13,090.55	48,210.44	43,030.82	55,763.95
2 Expenses						
a) Cost of materials consumed	11,651.01	8,834.01	7,930.24	28,760.81	25,531.61	33,881.47
b) Purchase of stock – in – trade	602.51	261.24	196.66	1,719.52	734.00	295.11
c) Changes in inventories of finished goods, work- in – process and stock – in – trade	(356.85)	(619.59)	(721.93)	(996.52)	(1,143.29)	(1,414.59)
d) Employee benefits expense	1,026.51	651.56	605.66	2,298.06	1,777.01	2,431.75
e) Finance costs	23.34	34.39	20.45	73.40	66.58	106.89
f) Depreciation and amortization expense	333.07	300.76	258.95	902.81	721.02	922.05
g) Other expenses	1,964.29	1,540.75	1,152.03	4,961.23	3,861.54	5,416.95
Total expenses	15,243.88	11,003.14	9,442.06	37,719.30	31,548.47	41,639.63
3 Profit / (Loss) before tax (1-2)	3,802.37	3,539.38	3,648.49	10,491.14	11,482.35	14,124.32
4 Tax expenses						
a. Current Tax	845.68	767.93	788.13	2,115.67	2,407.62	2,929.21
b. Deferred Tax	(54.88)	163.82	77.19	253.45	167.04	274.29
5 Profit / (Loss) after tax (3-4)	3,011.57	2,607.62	2,783.17	8,122.03	8,907.69	10,920.82
Attributable to:						
(a) Owners of the Company	2,634.75	2,598.54	2,763.45	7,714.38	8,823.89	10,820.78
(b) Non-Controlling Interest	376.82	9.09	19.72	407.65	83.80	100.04
6 Other Comprehensive Income (OCI) (net of tax)	3.43	6.13	(5.71)	5.70	(17.14)	(1.94)
7 Total Comprehensive Income for the period (5+6)	3,015.00	2,613.76	2,777.46	8,127.73	8,890.55	10,918.88
Attributable to:						
(a) Owners of the Company	2,638.18	2,604.67	2,757.74	7,720.08	8,806.75	10,818.84
(b) Non-Controlling Interest	376.82	9.09	19.72	407.65	83.80	100.04
8 Paid-up Equity share capital (Face Value ₹ 1/- each)	11,595.01	2,291.50	2,318.71	11,595.01	2,318.71	2,291.50
9 Other Equity (Excluding Revaluation Reserve if any)						70,840.41
10 Earnings per Share (of ₹ 1/- each) (for Quarter and period ended not annualised):						
a) Basic & Diluted EPS (₹/Share)	0.26	0.22	0.24	0.70	0.77	0.94

Notes:

- 1 The above consolidated results were reviewed and recommended by the Audit Committee and approved at the meeting of the Board of Directors of the Company held on 13th February, 2026. The above results have been subjected to Limited Review by the Statutory Auditors of the Company. The Statutory Auditors have expressed an unqualified report on the above results.
- 2 This Statement is as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.
- 3 These financial results together with the results of previous period have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 Interim Financial Reporting prescribed under Section 133 of the companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
- 4 The Company mainly operates in a single primary business segment of Speciality Chemicals, therefore disclosure requirements as per Ind AS 108, "Operating Segments" are not applicable to the Company.

5 During the quarter ended December 31, 2025,

- a) Authorised share capital of the Company was increased from Rs. 2,800 Lakhs consisting of 14,00,00,000 equity shares of face value of Rs 2 each to Rs 12,000 Lakhs consisting of 60,00,00,000 equity shares of Rs 2 each.
- b) The Board of Directors of the Company at their meeting held on September 27, 2025 have approved the sub-division/ split of equity shares of face value of Rs. 2/- each, fully paid-up, into equity shares of Rs 1/-each, fully paid up,
- Accordingly the Authorised Capital was also modified from 60,00,00,000 equity shares of Rs 2 each , to 120,00,00,000 equity shares of Rs 1 each.
- c) The shareholders of the Company have approved, the issuance of bonus shares, in the proportion of 4:1, i.e 4 bonus equity share of ₹ 1 each for every 1 fully paid-up equity share held as on the record date. Accordingly, the Company has allotted 91,66,00,720 equity shares as bonus shares on October 31st, 2025 by utilisation of share premium.
- d) The Fund raising committee of the Board has allotted 1,37,50,000 equity shares pursuant to the conversion of 13,75,000 warrants at a price of Rs 34.60- per share. Consequently, the paid-up share capital as of 31st December 2025 stood at Rs. 11,595.01/- Lakhs

During the FY 24-25 , an amount of Rs 2,272.01 lakhs was received against 25% of total issue of 26,26,600 issued at a price of Rs. 346 /- per warrant was received upon allotment of warrants.

During the quarter ended 31st December 2025, the Warrant holders holding 12,51,600 warrants have failed to exercise their rights to acquire Equity Share underlying the said Warrants, on or before November 21, 2025, and as a result 12,51,600 Warrants stands cancelled/lapsed and consideration of Rs 1,082.63 /- Lakhs , received by the Company from the Warrant holders, towards allotment of said Warrants, has been forfeited in accordance with the terms of Issue of the said Warrants and the provisions of the SEBI ICDR Regulations, 2018 . The said amount forfeited has been transferred to Capital Reserve.

6 Earnings per share

The impact of the above mentioned stock split and bonus shares issued was considered in the computation of basic and diluted Earning per share (EPS) and Total Equity (post-tax) per share for diluted Earning per share (EPS) and Total Equity (post-tax) per share for the quarter and nine months ended December 31st, 2025 and comparative figures till prior period have also been adjusted to give effect to such sub-division/split and bonus issue in accordance with requirements under Ind AS 33 - Earnings per share.

7 Effect of Labour Codes

On November 21, 2025, the Government of India notified the four new Labour Codes namely the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020.

Provisions of the previous labour Acts and their rules, notifications, etc. continue to remain in force till final notification of new Rules, etc under the Code, to the extent these are in line with the Codes.

The company is evaluating new labour laws. The impact of the same on the financials of the company, if any, shall be accounted for in the Financials for Quarter and Year Ending on 31-03-2026.

8 Step Down Subsidiary Acquisition.

On December 09, 2025, Finecotex Chemical Limited ("the Company") through its wholly-owned subsidiary Finecotex Biotex Healthguard FZE, acquired equity interests in the Companies detailed herein below :

The Company acquired a **53.33% stake** in each of the following four entities, which have now become step-down subsidiaries of the Company :

- 1) CrudeChem Technology LLC
- 2) FrackMex Equipment and Services LLC
- 3) Lonestar Technoboost LLC
- 4) Oil Pro Advantage INC

9 Events occurring after End of the Quarter under review :

On **17th January 2026**, the Board of Directors approved the allotment of equity shares pursuant to the conversion of Warrants .

Following the receipt of balance application monies, 5,00,000 warrants were converted into 50,00,000 Equity Shares of Rs. 1/- each.

This figure accounts for the Rs. 2/- to Rs. 1/- Stock Split and the 4:1 Bonus Issue.

As of the date of this report, the total paid-up share capital of the Company stands increased to Rs. 116.45 Lakhs comprising 1,16,45,00,900 equity shares of Rs. 1/- each.

- 10 Previous periods figure have been regrouped, rearranged, reclassified wherever necessary to correspond with those of the current period.
- 11 The Notes on the above results were approved at the meeting of the Board of Directors of the Company held on 13th February , 2026.

For and on behalf of Board of Directors

SURENDRA
DEVIPRASAD
TIBREWALA

Digitally signed by SURENDRA
DEVIPRASAD TIBREWALA
Date: 2026.02.13 18:06:18
+05'30'

Surendra Tibrewala
Chairman & Managing Director
DIN 00218394

SANJAY
SURENDRA
TIBREWALA

Digitally signed by SANJAY
SURENDRA TIBREWALA
Date: 2026.02.13 18:06:56 +05'30'

Sanjay Tibrewala
CFO & Executive Director
DIN 00218525

Place: Mumbai
Date: 13th February , 2026.

Independent Auditor's Review Report on the Standalone Unaudited Quarter and Nine months ended December 31,2025 Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

**Review Report to
The Board of Directors
Fineotex Chemical Limited**

1. We have reviewed the accompanying statement of Standalone Unaudited financial results (the "Statement") of Fineotex Chemical Limited (the "Company") for the quarter and nine months ended December 31, 2025, (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under Section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Fineotex Chemical Limited**Independent Auditor's Review Report on the Unaudited Standalone Quarter and Nine months ended December 31,2025 Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.**

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS 34 specified under Section 133 of Act as amended, read with relevant rules issued thereunder and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For ASL & Co.
Chartered Accountants
(Regn No. 101921W)



(Shikha Jain)
Partner
Membership No.: 136484
UDIN: 26136484IZWQIV3496
Place: Mumbai
Date: February 13, 2026



FCL FINEOTEX CHEMICAL LIMITED

(Company Identification Number: L24100MH2004PLC144295)

Regd. Off.: 42/43, Manorama Chambers, S V Road, Bandra (W), Mumbai 400050

Tel: 022-26559174-77, Fax: 022-22659178, Email: info@fineotex.com, Web: www.fineotex.com

(₹ In lakhs)

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER, 2025						
PARTICULARS	Quarter ended			Nine months ended		Year Ended
	31-Dec-25	30-Sep-25	31-Dec-24	31-Dec-25	31-Dec-24	31-Mar-25
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Income						
a) Revenue from operation	9,647.47	10,454.79	10,930.70	29,927.85	33,127.61	43,922.21
b) Other Income	1,127.62	1,243.27	453.25	3,367.59	1,983.45	2,748.51
Total Income	10,775.08	11,698.06	11,383.95	33,295.44	35,111.06	46,670.72
2 Expenses						
a) Cost of materials consumed	5,915.17	6,975.26	7,344.44	19,421.50	21,040.95	28,408.75
b) Purchase of stock – in – trade	-	-	-	-	131.12	131.12
c) Changes in inventories of finished goods, work- in – process and stock – in – trade	(268.77)	(440.85)	(801.90)	(654.69)	(1,030.11)	(1,413.98)
d) Employee benefits expense	602.47	563.84	527.23	1,704.88	1,542.08	2,110.08
e) Finance costs	11.89	13.30	16.59	35.81	37.68	58.77
f) Depreciation and amortization expense	214.56	209.76	188.64	625.13	529.67	716.04
g) Other expenses	1,207.22	1,045.22	897.51	3,254.01	2,891.13	4,118.41
Total expenses	7,682.54	8,366.53	8,172.51	24,386.64	25,142.52	34,129.19
3 Profit / (Loss) before tax (1-2)	3,092.54	3,331.53	3,211.44	8,908.81	9,968.54	12,541.53
4 Tax expenses						
a. Current Tax	600.00	650.00	695.00	1,626.07	2,038.16	2,578.06
b. Deferred Tax	(72.71)	160.69	67.62	207.28	151.76	240.80
5 Profit / (Loss) after tax (3-4)	2,565.25	2,520.84	2,448.82	7,075.46	7,778.62	9,722.67
6 Other Comprehensive Income (OCI) (net of tax)	3.43	6.13	(5.71)	5.70	(17.14)	(1.94)
7 Total Comprehensive Income for the period (5+6)	2,568.68	2,526.97	2,443.11	7,081.16	7,761.48	9,720.73
8 Paid-up Equity share capital (Face Value ₹ 1/- each)	11,595.01	2,291.50	2,318.71	11,595.01	2,318.71	2,291.50
9 Other Equity (Excluding Revaluation Reserve if any)						60,642.26
10 Earnings per Share (of ₹ 1/- each) (for Quarter and period ended not annualised):						
a) Basic & Diluted EPS (₹/Share)	0.22	0.22	0.21	0.61	0.67	0.84

Notes:

- 1 The above results were reviewed and recommended by the Audit Committee and approved at the meeting of the Board of Directors of the Company held on 13th February, 2026. The above results have been subjected to Limited Review by the Statutory Auditors of the Company. The Statutory Auditors have expressed an unqualified report on the above results.
- 2 This Statement is as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.
- 3 These financial results together with the results of previous period have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 Interim Financial Reporting prescribed under Section 133 of the companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
- 4 The Company mainly operates in a single primary business segment of Speciality Chemicals, therefore disclosure requirements as per Ind AS 108, "Operating Segments" are not applicable to the Company.
- 5 **During the quarter ended December 31, 2025,**
 - a) Authorised share capital of the Company was increased from Rs. 2,800 Lakhs consisting of 14,00,00,000 equity shares of face value of Rs 2 each to Rs 12,000 Lakhs consisting of 60,00,00,000 equity shares of Rs 2 each.
 - b) The Board of Directors of the Company at their meeting held on September 27, 2025 have approved the sub-division/ split of equity shares of face value of Rs. 2/- each, fully paid-up, into equity shares of Rs 1/-each, fully paid up, Accordingly the Authorised Capital was also modified from 60,00,00,000 equity shares of Rs 2 each, to 120,00,00,000 equity shares of Rs 1 each.
 - c) The shareholders of the Company have approved, the issuance of bonus shares, in the proportion of 4:1, i.e 4 bonus equity share of ₹ 1 each for every 1 fully paid-up equity share held as on the record date. Accordingly, the Company has allotted 91,66,00,720 equity shares as bonus shares on October 31st, 2025 by utilisation of share premium.
 - d) The Fund raising committee of the Board has allotted 1,37,50,000 equity shares pursuant to the conversion of 13,75,000 warrants at a price of Rs 34.60- per share. Consequently, the paid-up share capital as of 31st December 2025 stood at Rs. 11,595.01/- Lakhs

During the FY 24-25, an amount of Rs 2,272.01 lakhs was received against 25% of total issue of 26,26,600 issued at a price of Rs. 346 /- per warrant was received upon allotment of warrants.

During the quarter ended 31st December 2025, the Warrant holders holding 12,51,600 warrants have failed to exercise their rights to acquire Equity Share underlying the said Warrants, on or before November 21, 2025, and as a result 12,51,600 Warrants stands cancelled/lapsed and consideration of Rs 1,082.63 /- Lakhs, received by the Company from the

6 Earnings per share

The impact of the above mentioned stock split and bonus shares issued was considered in the computation of basic and diluted Earning per share (EPS) and Total Equity (post-tax) per share for diluted Earning per share (EPS) and Total Equity (post-tax) per share for the quarter and nine months ended December 31st, 2025 and comparative figures till prior period

7 Effect of Labour Codes

On November 21, 2025, the Government of India notified the four new Labour Codes namely the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020.

Provisions of the previous labour Acts and their rules, notifications, etc. continue to remain in force till final notification of new Rules, etc under the Code, to the extent these are in line with the Codes.

The company is evaluating new labour laws. The impact of the same on the financials of the company, if any, shall be accounted for in the Financials for Quarter and Year Ending on 31-03-2026.

8 Step Down Subsidiary Acquisition.

On December 09, 2025, Fineotex Chemical Limited ("the Company") through its wholly-owned subsidiary Fineotex Biotex Healthguard FZE, acquired equity interests in the Companies detailed herein below :

The Company acquired a **53.33% stake** in each of the following four entities, which have now become step-down subsidiaries of the Company :

- 1) CrudeChem Technology LLC
- 2) FrackMex Equipment and Services LLC
- 3) Lonestar Technoboost LLC
- 4) Oil Pro Advantage INC

9 Events occurring after End of the Quarter under review :

On 17th January 2026, the Board of Directors approved the allotment of equity shares pursuant to the conversion of Warrants .

Following the receipt of balance application monies, 5,00,000 warrants were converted into 50,00,000 Equity Equity Shares of Rs. 1/- each. This figure accounts for the Rs. 2/- to Rs. 1/- Stock Split and the 4:1 Bonus Issue.

As of the date of this report, the total paid-up share capital of the Company stands increased to Rs. 116.45 Lakhs comprising 1,16,45,00,900 equity shares of Rs. 1/- each.

10 Previous periods figure have been regrouped, rearranged, reclassified wherever necessary to correspond with those of the current period.

11 The Notes on the above results were approved at the meeting of the Board of Directors of the Company held on 13th February, 2026.

For and on behalf of Board of Directors

SURENDRA
DEVIPRASAD
TIBREWALA

Digitally signed by SURENDRA
DEVIPRASAD TIBREWALA
Date: 2026.02.13 18:06:39
+05'30'

Surendra Tibrewala
Chairman & Managing Director
DIN 00218394

SANJAY
SURENDRA
TIBREWALA

Digitally signed by
SANJAY SURENDRA
TIBREWALA
Date: 2026.02.13 18:07:13
+05'30'

Sanjay Tibrewala
CFO & Executive Director
DIN 00218525

Place: Mumbai

Date: 13th February, 2026.